RJA
FBLG icon

Raymond James & Associates’s FibroBiologics FBLG Stock Holding History

Raymond James & Associates’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$54.5K Hold
882
– – ﹤0.01% 3847
2024
Q2 		$88K Buy
+882
New +$168K ﹤0.01% 3743

Other funds holding FBLG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AIFAIM
American Institute for Advanced Investment Management Scottsdale, Arizona $173M AUM 25.3% 1-Year Est. Return

Raymond James & Associates's FBLG Position: Q3 2024 in Review

Raymond James & Associates held its FibroBiologics (FBLG) position steady in Q3 2024 at 882 shares worth $54.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3847.

Raymond James & Associates first reported a position in FBLG in Q2 2024 and has held it in 2 quarters since. The position peaked at $88K in Q2 2024. 61 funds tracked by Wall St. Rank hold FBLG as of Q3 2024.

  • Raymond James & Associates held 882 shares of FibroBiologics worth $54.5K as of Q3 2024.
  • Raymond James & Associates left its FibroBiologics share count unchanged in Q3 2024.
  • FibroBiologics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3847 holding.
  • Raymond James & Associates first reported a position in FibroBiologics in Q2 2024 and has held it in 2 quarters since.
  • Raymond James & Associates's FibroBiologics position peaked at $88K in Q2 2024.
  • 61 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.